{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-019108","form_type":"8-K","ticker":"RNGE","cik":"0001438943","company_name":"RANGE IMPACT, INC.","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.115168+00:00","generated_at":"2026-06-29T16:30:20.917299+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vitality Biopharma receives FDA Orphan Drug Designation for VBX-100 for pediatric ulcerative colitis","bullets":["FDA granted Orphan Drug Designation to VBX-100, a glycosylated cannabinoid prodrug, for pediatric ulcerative colitis.","Orphan Drug Designation provides seven-year market exclusivity upon FDA approval, tax credits, and fee exemptions.","Vitality has developed over 100 novel glycosylated cannabinoid compounds using proprietary enzymatic bioprocessing.","VBX-100 targets inflammatory conditions of the gastrointestinal tract; company plans to accelerate research."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-019108","json":"https://secwatch.observer/filing/0001493152-21-019108.json","markdown":"https://secwatch.observer/filing/0001493152-21-019108.md","text":"https://secwatch.observer/filing/0001493152-21-019108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438943/000149315221019108/0001493152-21-019108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438943/000149315221019108/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T16:30:20.917299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}